Tesamorelin 10mg

Buy high-purity tesamorelin (10mg) in Australia. Third-party lab tested at >99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.

About tesamorelin

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH 1–44), modified at the N-terminus with a trans-3-hexenoyl group that markedly increases its resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). The modification gives tesamorelin a substantially longer functional half-life than native GHRH while preserving its ability to bind and activate the GHRH receptor on pituitary somatotrophs.

In published research, tesamorelin is one of the most extensively characterised GHRH analogues, with study interest concentrated on the GH/IGF-1 axis, visceral adipose tissue dynamics and metabolic markers in animal and human research populations.

Optic Labs supplies tesamorelin as a lyophilised powder in 10mg research vials, third-party HPLC tested to >99% purity. The product is distributed Australian-domestic from Sydney, NSW, for in vitro and laboratory research applications. Tesamorelin is supplied strictly for laboratory research, development or analytical use and is not intended for human consumption.

Product specifications

• Compound: Tesamorelin (trans-3-hexenoyl-GHRH 1–44)
• CAS number: 218949-48-5
• Molecular formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular weight: ~5196 g/mol
• Sequence: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂ (44 amino acids)
• Form: Lyophilised powder
• Purity: >99% by HPLC
• Available size: 10mg vial
• Storage: 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.
• Origin: Manufactured to research-grade specifications, third-party HPLC verified
• Shipping: Australia-wide domestic dispatch from Sydney, NSW

Research background

Tesamorelin was originally developed by Theratechnologies in the early 2000s as a stabilised analogue of human GHRH, with the trans-3-hexenoyl N-terminal modification specifically engineered to resist DPP-IV cleavage.

The compound has been extensively studied in published clinical and preclinical research, most notably in the context of HIV-associated visceral adipose tissue accumulation, where it became the first GHRH analogue to receive a regulatory indication in that population.

In Australian and broader research contexts, tesamorelin is examined as a research-use compound for studying GHRH-axis biology.

• GHRH receptor pharmacology: in pituitary cell-culture studies, tesamorelin binds the GHRH receptor with affinity comparable to native GHRH 1–44 and stimulates pulsatile growth hormone release through the cAMP/PKA pathway.
• GH and IGF-1 axis research: in published research populations, tesamorelin administration has been associated with sustained increases in endogenous GH pulse amplitude and downstream IGF-1, without the supraphysiological GH exposures seen with exogenous recombinant GH.
• Visceral adipose tissue research: in published lipodystrophy studies, tesamorelin has been investigated for its effects on visceral adipose tissue volume measured by CT or MRI, with research interest in the lipolytic effects of restored physiological GH pulsatility.
• Metabolic markers: research has examined effects on triglycerides, non-HDL cholesterol, adiponectin and hepatic fat fraction in study populations with metabolic dysregulation.
• Hepatic steatosis models: in published research on non-alcoholic fatty liver disease (NAFLD) cohorts, tesamorelin has been studied for effects on liver fat content and markers of hepatic inflammation and fibrosis.
• Cognitive and neurological research: exploratory research has examined tesamorelin in the context of GH-axis modulation and cognitive performance in older research populations.
• Pharmacokinetic stability: the trans-3-hexenoyl modification gives tesamorelin a functional duration of action sufficient to support once-daily dosing protocols in published research, in contrast to the very short half-life of native GHRH.

For a plain-language overview of peptides, see our what are peptides explainer. Researchers working with reconstitution should also reference our peptide reconstitution guide, and for laboratory injection protocols our subcutaneous injection protocol article.

Reconstitution and handling

Tesamorelin is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use in any laboratory protocol. A common laboratory approach for the 10mg vial is reconstitution in 2ml of bacteriostatic water to yield a 5mg/ml working stock, or in 1ml for a 10mg/ml stock.

The bacteriostatic water should be drawn into a sterile syringe and injected slowly down the inside wall of the lyophilised vial, allowing the peptide cake to dissolve passively rather than through agitation. Tesamorelin is sensitive to heat and freeze-thaw cycling; reconstituted stocks should be aliquoted, refrigerated at 2–8°C and protected from light, with research stocks typically used within 30 days.

For dilution maths across alternative volumes, see our reconstitution calculator guide. For long-term storage protocols, see our peptide storage guide.

Commonly stacked research peptides

In published research and laboratory protocols, tesamorelin is often examined alongside other GH-axis, metabolic and longevity research compounds:

• CJC-1295 + Ipamorelin — GHRH/GHRP combination commonly co-investigated with tesamorelin in research on the GH-axis and pulsatile GH release.
• AOD-9604 — GH fragment studied alongside tesamorelin in adipose tissue and lipolysis research models.
• Retatrutide — GLP-1/GIP/glucagon triple agonist examined in parallel with tesamorelin in metabolic and visceral adiposity research designs.
• MOTS-c — mitochondrial-derived peptide investigated for metabolic and energy-balance effects alongside GH-axis research.
• NAD+ — co-investigated in metabolic and longevity research alongside GH-axis modulation.

For broader context on combined research designs, see our peptide research stacks overview.

Frequently asked questions

Is tesamorelin legal in Australia?

Tesamorelin is not currently registered with the Therapeutic Goods Administration (TGA) for any therapeutic indication in Australia. Optic Labs supplies tesamorelin strictly as a research chemical for in vitro and preclinical laboratory research — not for human consumption, clinical use or any therapeutic application. For a full overview of how the TGA treats research peptides in Australia, see our peptide legality and TGA compliance guide.

What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH 1–44), modified at the N-terminus with a trans-3-hexenoyl group that resists enzymatic degradation. In published research it stimulates pulsatile endogenous GH release through the GHRH receptor on pituitary somatotrophs. For a plain-language overview of peptides, see our what are peptides explainer.

What does tesamorelin do in published research?

In published clinical and preclinical research, tesamorelin is studied for its effects on endogenous GH pulse amplitude, IGF-1 levels, visceral adipose tissue volume, hepatic fat fraction and a range of metabolic markers including triglycerides and adiponectin. These observations are research findings only and do not constitute therapeutic claims.

How does tesamorelin compare with CJC-1295 in research?

Both tesamorelin and CJC-1295 are GHRH analogues, but they differ in design.

Tesamorelin is the full GHRH 1–44 sequence with an N-terminal trans-3-hexenoyl modification for DPP-IV resistance and is supported by the largest published clinical research dataset of any GHRH analogue. CJC-1295 (no DAC) is a shorter GHRH 1–29 analogue with several amino acid substitutions for stability, and is most often studied in combination with a ghrelin-receptor agonist such as ipamorelin.

How is tesamorelin supplied?

Optic Labs supplies tesamorelin as a lyophilised powder in 10mg glass research vials. Each vial is sealed with a tamper-evident closure. Certificates of analysis showing HPLC purity testing are available on request.

How much bacteriostatic water do I mix with a 10mg tesamorelin vial?

For a 10mg vial, 2ml of bacteriostatic water yields a 5mg/ml working stock; 1ml yields a 10mg/ml stock; 5ml yields a 2mg/ml stock. Choose a volume based on the concentrations required by the research protocol. For a worked example with unit conversions, see our reconstitution calculator guide.

How should reconstituted tesamorelin be stored?

Reconstituted tesamorelin should be stored at 2–8°C, protected from light, and used within approximately 30 days. For longer-term storage, aliquoting and freezing at −20°C or below is preferred to limit freeze-thaw degradation. Full handling protocols are covered in our peptide storage research guide.

Where does Optic Labs ship to?

Optic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.

Legal disclaimer

All products on this site are supplied for laboratory research, development or analytical use only. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the Therapeutic Goods Administration (TGA) or the APVMA and are not intended to diagnose, treat, cure or prevent any disease.

Optic Labs is not a compounding pharmacy or manufacturing facility as defined under the Therapeutic Goods Act 1989, and is not a registered provider of scheduled medicines or therapeutic goods.